Miss Holly Evans
Clinical Medicine, School of Medicine and Population Health
Senior Research Technician
h.r.evans@sheffield.ac.uk
+44 114 215 9209
+44 114 215 9209
The Medical School
Full contact details
Miss Holly Evans
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Publications
-
Journal articles
- Evidence for peri-lacunar remodeling and altered osteocyte lacuno-canalicular network in mouse models of myeloma-induced bone disease. JBMR Plus, 8(9). View this article in WRRO
- Metastatic Infiltration of Nervous Tissue and Periosteal Nerve Sprouting in Multiple Myeloma-Induced Bone Pain in Mice and Human. The Journal of Neuroscience, 43(29), 5414-5430.
- Retraction Note: The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature, 617(7959), 208-208.
- Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma. Journal for ImmunoTherapy of Cancer, 11(1), e005319-e005319.
- P-133: Myeloma-induced bone pain: lessons learnt from a localized, immunocompetent mouse model. Clinical Lymphoma Myeloma and Leukemia, 22, S108-S108.
- Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects By Inhibiting c-Myc Expression in Vitro and In Vivo. Blood, 138(Supplement 1), 1594-1594.
- ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation. Stem Cell Research & Therapy, 11(1).
- Correction: LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution. Cancer Research, 79(19), 5123-5123.
- TGFβ inhibition stimulates collagen maturation to enhance bone repair and fracture resistance in a murine myeloma model. Journal of Bone and Mineral Research. View this article in WRRO
- PYY is a negative regulator of bone mass and strength. Bone, 127, 427-435.
- Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models. Journal of Bone and Mineral Research. View this article in WRRO
- ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.. PLoS One, 13(6). View this article in WRRO
- The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1‐Fluoro‐2‐(Imidazo‐[1,2‐α]Pyridin‐3‐yl)‐Ethyl‐Bisphosphonate). Journal of Bone and Mineral Research, 32(9), 1860-1869. View this article in WRRO
- An Essential Physiological Role for MCT8 in Bone in Male Mice. Endocrinology, 158(9), 3055-3066. View this article in WRRO
- Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods. Bone, 83, 9-16.
- Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model. British Journal of Haematology, 172(1), 64-79.
- The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature, 522(7554), 106-110. View this article in WRRO
- Thyroid hormone receptor α mutation causes a severe and thyroxine-resistant skeletal dysplasia in female mice.. Endocrinology, 155(9), 3699-3712.
- An N-ethyl-N-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excess.. Endocrinology, 155(3), 908-922.
- Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacologica Sinica, 34(5), 699-709.
- Autosomal dominant hypercalciuria in a mouse model due to a mutation of the epithelial calcium channel, TRPV5.. PLoS One, 8(1), e55412. View this article in WRRO
- A mouse with an N-ethyl-N-nitrosourea (ENU) induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis. PLoS ONE, 7(8). View this article in WRRO
- Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength.. PLoS Genet, 8(8), e1002858. View this article in WRRO
- Mice lacking the calcineurin inhibitor Rcan2 have an isolated defect of osteoblast function.. Endocrinology, 153(7), 3537-3548.
- Erratum: Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. Journal of Bone and Mineral Research, 27(9), 2036-2037.
- Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia.
- LOXL2-mediated matrix remodeling in metastasis and mammary gland involution.. Cancer Res, 71(5), 1561-1572.
- Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.. J Bone Miner Res, 25(12), 2633-2646.
- Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. P NATL ACAD SCI USA, 107(16), 7604-7609.
- Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.. J Bone Miner Res, 24(3), 425-436.
- Inhibiting Dickkopf-1 (Dkk-1) prevents the development of osteolytic bone disease in multiple myeloma. CALCIFIED TISSUE INT, 83(1), 6-6.
- RAP-011, a soluble activin receptor type IIA IgG-Fc fusion protein, is a novel bone anabolic agent that prevents bone disease in multiple myeloma. CLIN EXP METASTAS, 25, 64-64.
- Mutations in VAPB are not associated with sporadic ALS.. Neurology, 68(22), 1951-1953.
- An essential physiological role for MCT8 in bone. Endocrine Abstracts.
- The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-fluoro-2-(imidazo-[1,2 alpha]pyridin-3-yl)ethyl-bisphosphonate), with reduced bone affinity, which is as effective as zoledronate in the treatment of myeloma bone disease in JJN3-NOD/SCID-[gamma] mice. Bone Abstracts.
- NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease. PLOS ONE, 10(3), e0119546-e0119546. View this article in WRRO
- TR[alpha] mutation causes a severe and thyroxine-resistant skeletal dysplasia. Endocrine Abstracts.
- An N-ethyl-N-nitrosourea induced Corticotrophin releasing hormone promoter mutation provides a mouse model of Cushing's syndrome. Endocrine Abstracts, 1-1.
- Bone Mineral Content and Density.
- A mouse model for spondyloepiphyseal dysplasia congenita with secondary osteoarthritis due to a Col2a1 mutation. J Bone Miner Res..
Conference proceedings papers
- BS74 Assessment of fluid status in porcine models of heart failure and pulmonary hypertension. Basic Science
- Mechanisms of Bone Pain in Multiple Myeloma: Involvement of Periosteal Bone Sprouting. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 55-56)
- Myeloma-induced bone pain: lessons learnt from a localized, immunocompetent mouse model. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol. 22 (pp S108-S108)
- Machine Learning Approaches for Cancer Bone Segmentation from Micro Computed Tomography Images. PROCEEDINGS OF 2020 23RD INTERNATIONAL CONFERENCE ON INFORMATION FUSION (FUSION 2020) (pp 1263-1268)
- Machine Learning Approaches for Cancer Bone Segmentation from Micro Computed Tomography Images. 2020 IEEE 23rd International Conference on Information Fusion (FUSION), 6 July 2020 - 9 July 2020. View this article in WRRO
- Development of a Novel Human Anti-OPG Antibody That Attenuates Experimental Pulmonary Arterial Hypertension. CIRCULATION, Vol. 136
- Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the development of osteolytic bone disease in the 5T2MM murine model of myeloma. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 153 (pp 7-7)
- Tumour-secreted lox mediates osteolytic bone metastases prior to metastatic tumour cell colonisation. BONE, Vol. 48(1) (pp S21-S21)
- Imaging and quantitation of multiple myeloma in calvariae. BONE, Vol. 47 (pp S328-S328)
- Inhibiting glycogen synthase kinase-3 (GSK-3) prevents the development of myeloma bone disease. BONE, Vol. 44 (pp S53-S54)
- Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the formation of osteolytic bone disease in the 5T2MM murine model of myeloma. BONE, Vol. 44 (pp S55-S55)
- Microct analysis of P2Y1 and P2Y2 receptor knockout mice demonstrates significant changes in bone phenotype. CALCIFIED TISSUE INT, Vol. 83(1) (pp 2-3)
- MicroCT analysis of P2Y1 and P2Y2 receptor knockout mice demonstrates significant changes in bone phenotype. PURINERG SIGNAL, Vol. 4 (pp S176-S176)
- A soluble activin type II receptor prevents the development of myeloma bone disease. CANCER TREATMENT REVIEWS, Vol. 34 (pp S56-S57)
- Inhibiting dickkopf-1 (Dkk-1) prevents the development of osteolytic bone disease in multiple myeloma. CANCER TREATMENT REVIEWS, Vol. 34 (pp S52-S52)
- A soluble activin type II receptor prevents myeloma bone disease. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1118-1118)
- A soluble activin type II receptor prevents myeloma bone disease. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol. 92(6) (pp 133-133)
Preprints
- Metastatic infiltration of nervous tissue and periosteal nerve sprouting in multiple myeloma induced bone pain, Cold Spring Harbor Laboratory.